Human papillomavirus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer ...

A NEW test has been found to identify head and neck cancers caused by human papillomavirus (HPV) up to 10 years before ...

Researchers hope the advanced warning could enable earlier, less invasive treatments with fewer side effects and better ...

Mass General Brigham’s HPV-DeepSeek test achieves much earlier blood-based cancer detection, opening new path for ...

Head and neck cancer shows major shifts in cellular energy use, blocking these pathways can unlock new cancer immunotherapies ...

Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year.

Mass General Brigham researchers have developed a groundbreaking blood test named HPV-DeepSeek that can detect HPV-associated ...

A new liquid biopsy blood test could help detect cases of human papillomavirus (HPV)-associated head and neck cancers with ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the Company’s Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Neoadjuvant ...

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes it has a potential new standard of care for head and neck squamous cell ...

Bicara Therapeutics Inc. announced the publication of updated interim data from its Phase 1/1b clinical trial of ficerafusp alfa combined with pembrolizumab for treating recurrent/metastatic head and ...